Find information on thousands of medical conditions and prescription drugs.

Aggrenox

Dipyridamole is a drug that inhibits platelet aggregation. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
  • It inhibits the enzyme adenosine deaminase which normally breaks down adenosine. This inhibition leads to increased levels of adenosine. Adenosine activates the enzyme adenylate cyclase which leads to increased cyclic AMP (cAMP) synthesis.
  • Dipyridamole also inhibits the enzyme phosphodiesterase which normally breaks down cAMP.

Both of these mechanisms lead to increased levels of cAMP within platelets. cAMP impairs platelet aggregation.

Modified release dipyridamole is used in conjunction with aspirin (Aggrenox®) in the secondary prevention of stroke and transient ischemic attack.

Read more at Wikipedia.org


[List your site here Free!]


Aggrenox - Brief Article - Statistical Data Included
From Family Pratice News, 1/15/00 by Elizabeth Mechcatie

(aspirin/extended-release dipyridamole, Boehringer Ingelheim)

A combination of two antiplatelets for preventing stroke in people who have had a previous stroke or transient ischemic attack (TIA). This is the first antiplatelet combination studied as long-term preventive therapy in this population and the first product that combines two antiplatelet drugs in one.

* Recommended Dosage: One capsule containing 25 mg of aspirin and 200 mg of extended-release dipyridamole twice a day.

* Special Considerations: In studies, bleeding rates among Aggrenox-treated patients were similar to those treated with aspirin. About 5% more of treated patients had headaches than those on placebo. European physicians have found that stopping treatment for a few days, restarting treatment at one capsule a day, and increasing to two a day after a few days has helped people who develop headaches with initial treatment, said Dr. Greg Albers, director of Stanford University's stroke center.

The extended-release dipyridamole formulation is not available separately. The immediate-release formulation is available in smaller doses and the Food and Drug Administration indicates in the package insert that it should not be used with aspirin to substitute for Aggrenox, he noted.

* Comment: Approval was based on the results of the European Stroke Prevention Study 2 of over 6,000 people who had had an ischemic stroke or TIA within 3 months of the study. Over 24 months, those treated with Aggrenox had a reduced risk of recurrent stroke that was 22% greater than those treated with 50 mg of aspirin a day alone, 24% greater than those on 400 mg/day extended-release dipyridamole dose, and 37% greater than those on placebo.

Current guidelines for TIA and ischemic stroke prevention recommend aspirin as the first choice, but refer to the three alternatives now available: Aggrenox, ticlopidine, and clopidogrel, said Dr. Albers, chair of the recently published guidelines on the prevention of stroke after TIA (Stroke 30[9]:1991-94, 1999). These three drugs have never been directly compared, but data from separate studies that have compared them with aspirin suggest that Aggrenox may be more effective than clopidogrel, shown to reduce the risk of stroke 8% over aspirin alone, said Dr. Albers. Both have a good side effect profile, while ticlopidine, shown to reduce the risk of stroke 21% over aspirin alone, has some dangerous side effects in a small proportion of patients, he added.

Aspirin is considered the first choice because it is more cost effective than the others, which are more expensive, he added. Dr. Albers, professor of neurology at Stanford, has served on Boehringer Ingelheim's advisory board and has given lectures for the company, but has no financial interests in the company.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Aggrenox
Home Contact Resources Exchange Links ebay